Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, ACE-031 Vector   (CAT#: GTVCR-WQ266MR)

This product GTVCR-WQ266MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting MSTN. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_005259.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, ACE-031 Vector (GTVCR-WQ266MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ795MR IVTScrip™ pT7-VEE-mRNA-Anti-IL21, BOS161721 Vector Vector BOS161721
GTVCR-WQ626MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSLN, BAY 2287409 Vector Vector BAY 2287409
GTVCR-WQ86MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDGFRA, 3G3 Vector Vector 3G3
GTVCR-WQ1495MR IVTScrip™ pT7-VEE-mRNA-Anti-IL1B, IL-1 Trap Vector Vector IL-1 Trap
GTVCR-WQ1642MR IVTScrip™ pSP6-VEE-mRNA-Anti-PCSK9, JS002 Vector Vector JS002
GTVCR-WQ278MR IVTScrip™ pSP6-VEE-mRNA-Anti-GDF11, ACE-536 Vector Vector ACE-536
GTVCR-WQ2035MR IVTScrip™ pT7-VEE-mRNA-Anti-MSLN, MORAb-009 Vector Vector MORAb-009
GTVCR-WQ527MR IVTScrip™ pT7-VEE-mRNA-Anti-B4GALNT1, APN311 Vector Vector APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW